Alfacell Achieves Full Patient Enrollment Milestone
Press Release Source: Alfacell Corporation
BLOOMFIELD, N.J., Feb. 27 /PRNewswire-FirstCall/ — Alfacell Corporation (Nasdaq: ACEL – News) today announced that the full enrollment target of 316 patients has been reached for the international, confirmatory Phase IIIb registration trial evaluating ONCONASE® (ranpirnase), the Company’s lead investigational drug candidate, as a treatment for unresectable malignant mesothelioma (UMM).The Company [...]
